公司概述
Humana Inc. operates as a major provider of medical and specialty insurance products within the United States, primarily functioning through its Insurance and CenterWell segments to deliver health insurance benefits, wellness programs, and chronic care management services. The company is firmly situated in the Healthcare sector, specifically within the Healthcare Plans industry, positioning it as a key participant in the administration of Medicare Advantage and other health coverage solutions. With a market capitalization of $23.80B and annual revenue reaching $129.66B over the trailing twelve months, Humana employs a substantial workforce of 67,060 individuals to support its extensive network of services. These financial dimensions, particularly the significant revenue volume relative to its market cap, indicate that the company generates substantial top-line income but maintains a valuation that reflects the capital-intensive nature of the healthcare insurance model, where operational efficiency is critical to converting revenue into profit.
财务健康
Humana reported total revenue of $129.66B, net income of $1.19B, and EBITDA of $3.57B for the trailing twelve months, highlighting a distinct gap between revenue and net income that reveals a high-cost structure typical of the insurance industry where claims payments and administrative expenses heavily impact the bottom line. The company generated free cash flow of $1.32B, which signifies a positive cash generation capability that provides financial flexibility to fund operations, service debt, or invest in strategic initiatives without relying solely on external financing. Profitability analysis shows a gross margin of 14.5%, an operating margin of -1.8%, and a profit margin of 0.9%, illustrating that while the company retains a portion of revenue after direct costs, operating expenses currently exceed operating income, resulting in a negative operating margin that compresses overall profitability. On the balance sheet, Humana holds $19.90B in cash against $13.27B in debt, supported by a debt-to-equity ratio of 74.81%, suggesting a relatively leveraged position where total debt is significantly lower than the cash reserve, yet the equity base is smaller relative to debt obligations. Liquidity is robust with a current ratio of 2.00, indicating that the company possesses twice the current assets necessary to cover its short-term liabilities, thereby ensuring strong short-term solvency. Management effectiveness is measured by a return on equity of 7.0% and a return on assets of 4.3%, metrics that suggest moderate efficiency in generating returns for shareholders and utilizing the asset base, respectively, within the constraints of the company's specific margin profile.
估值评估
The stock carries a trailing P/E ratio of 20.03 and a forward P/E of 12.95, where the substantial difference between these two metrics implies that the market expects a significant improvement in future earnings relative to current levels, potentially driven by cost management or premium growth. The price-to-book ratio stands at 1.35, indicating that the market values the company at 35% above its book value, which suggests a modest market premium that acknowledges the company's intangible assets and brand strength despite its current operating margin challenges. Alternative valuation metrics include a price-to-sales ratio of 0.18 and an EV/EBITDA of 4.83, figures that suggest the company is valued at a fraction of its sales and on an enterprise basis that is relatively low compared to traditional financial services peers, reflecting the market's cautious stance on its immediate profitability. Regarding trading ranges, the 52-week high is $315.35 and the 52-week low is $163.11; without a specific current price listed in the facts, the valuation context is strictly defined by this volatility range which establishes the boundaries of recent investor sentiment. The beta value is 0.45, meaning the stock exhibits less than half the price volatility of the broader market, positioning it as a lower-beta asset that moves less aggressively than the general equity index.
Growth & Income
Humana experienced revenue growth of 11.3% year-over-year, while earnings growth data is listed as N/A, which prevents a direct comparison of growth rates but implies that top-line expansion is occurring without a corresponding increase in reported net income for the period analyzed. As a dividend payer, the company offers a dividend yield of 1.8% with a payout ratio of 36.0%, a figure that indicates the dividend is funded by a sustainable portion of earnings, leaving a significant majority of profits available for reinvestment or debt reduction. The absence of earnings growth data complicates the assessment of whether the payout ratio is sustainable in the long term, as it relies heavily on maintaining or improving the current profit margin of 0.9% to keep the payout ratio from rising. Overall, the company presents a growth and income profile characterized by strong double-digit revenue expansion and a conservative dividend policy, though the lack of reported earnings growth suggests that investors are currently pricing in a transition period regarding profitability rather than earnings per share acceleration.